HMNC Brain Health
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Vasopressin V1B receptorSmall molecule | Major Depressive Disorder |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
5 August 2025Topline resultBH-200 (nelivaptan)OLIVE Phase 2b topline: primary endpoint (Subgroup C) not met; larger effects in Subgroups A and B
HMNC Brain Health · Source ↗
Financial reports
No financial reports recorded.